Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Meropol

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Medical Care|March 10, 2001
Measuring and predicting surgeons' practice styles for breast cancer treatment in older womenJ S Mandelblatt, C D Berg, N J Meropol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1996
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study GroupD Cunningham, J Zalcberg, I Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Research GroupN J Meropol, D E Wood, J Nemunaitis, et al.
American Journal of Hematology|June 1, 1992
Coincident Kaposi sarcoma and T-cell lymphoma in a patient with the Wiskott-Aldrich syndromeN J Meropol, D Hicks, J J Brooks, et al.
European Journal of Immunology|October 10, 2001
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cellsW E Carson, R Parihar, M J Lindemann, et al.
American Journal of Clinical Oncology|June 1, 1997
A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program TrialD J Vaughn, N J Meropol, C Holroyde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Impact of quality of life on patient expectations regarding phase I clinical trialsJ D Cheng, J Hitt, B Koczwara, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancerN J Meropol, Y M Rustum, N J Petrelli, et al.
Investigational New Drugs|January 1, 1995
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinomaN J Meropol, N J Petrelli, Y M Rustum, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumorsP J Creaven, L Pendyala, N J Meropol, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Medical Care|March 10, 2001
Measuring and predicting surgeons' practice styles for breast cancer treatment in older womenJ S Mandelblatt, C D Berg, N J Meropol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1996
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study GroupD Cunningham, J Zalcberg, I Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Research GroupN J Meropol, D E Wood, J Nemunaitis, et al.
American Journal of Hematology|June 1, 1992
Coincident Kaposi sarcoma and T-cell lymphoma in a patient with the Wiskott-Aldrich syndromeN J Meropol, D Hicks, J J Brooks, et al.
European Journal of Immunology|October 10, 2001
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cellsW E Carson, R Parihar, M J Lindemann, et al.
American Journal of Clinical Oncology|June 1, 1997
A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program TrialD J Vaughn, N J Meropol, C Holroyde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Impact of quality of life on patient expectations regarding phase I clinical trialsJ D Cheng, J Hitt, B Koczwara, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancerN J Meropol, Y M Rustum, N J Petrelli, et al.
Investigational New Drugs|January 1, 1995
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinomaN J Meropol, N J Petrelli, Y M Rustum, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumorsP J Creaven, L Pendyala, N J Meropol, et al.
Pageof 7